Categories
CEO & Collaborators Gonorrhea Medical Sexually Transmitted Infections

Why Hygee is important now: The Medical Case

We can start with a basic reality. The incidence of Sexually Transmitted Infections (STI) has reached epidemic proportions. This epidemic has serious implications for people and for our society, and they fall into two categories: health and economic. In this blog post, I’m going to talk about the effects on health, and I’ll talk about money and business next post.

There are a lot of STI. Some STI are viral, some caused by parasites, and some are bacterial. Bacterial infections are the most easily treatable because we have antibiotics for them. There are four major bacterial STI: chlamydia, gonorrhea, syphilis, and trichomoniasis. In the United States alone, the Centres for Disease Control reported this past August* that between 2013 and 2017 the number of people infected has increased greatly.

  • Chlamydia is the most common STI More than 1.7 million cases were diagnosed in 2017, 45% in 15- to 24-year-old women.
  • Gonorrhoea diagnoses increased 67% overall to 555,608 new infections in 2017, and nearly doubled among men (from 169,130 to 322,169). Infections in women increased in 2017 for the third year in a row.
  • Syphilis diagnoses increased 76%, although overall the numbers for this infection are much smaller than the other two.
  • The CDC did not report figures for trichomoniasis, but we can easily assume that the number of infections is growing rapidly as well,

Worldwide, the numbers are alarming, yet I have to point out, that the Americas, which include, Canada and the United States, two countries that invest a huge amount of money in modern healthcare systems, show higher rates of chlamydia and trichomoniasis than any other region.

As I said, all of these are curable with antibiotics, yet most cases aren’t diagnosed and aren’t treated. Untreated chlamydia can have severe effects on women and on the babies of untreated women. These include infertility, ectopic pregnancies, babies born blind or stillborn, and increased HIV risk.

New research suggests that one or two strains of chlamydia can also morph into trachoma, a tropical disease, which can cause blindness in the woman herself.

Why is this happening? Why do STI go undiagnosed and untreated, even in First World countries? There is a stigma around STI. People who are infected are shamed, and looked down on. Especially young woman who may be afraid to access medical help because their parents might be informed. In the US, healthcare is still subject to socioeconomic factors like poverty and access to clinics.

Hygee is important because it gives women the tool they need to get diagnosed on their own. A girl or woman will be able to buy the kit from a pharmacy or order it online. All she has to do is wear the pad for a minimum of four hours, put the pad in the envelope, tear off the envelope’s tab, and put it in the mail. The ETST partner lab will do the testing. She never puts her name on the test; there is just a number on the pad, the envelope, and the tab she keeps. A few days later, she can go online or phone the lab toll-free. She uses the number on the tab to access her results. If she is not infected, then no one will ever know she even decided to get tested.

If she is infected, the lab or the website will tell her what to do. She will have to see a doctor to get the antibiotics she needs to talk to kill the infection. She will have to be sure not to have unprotected sex until she has finished her course of antibiotics, and hardest of all, she should inform her partner(s) that she was infected that they have to get tested and treated as well. That is not so private, but it’s the only way to stop the spread of the disease.

Hygee will make it easy and private for women to get tested, and improved access to testing is the first step in stemming this massive, destructive epidemic.

The costs of STI infections aren’t just human health they are also economic. Next time.

Categories
CEO & Collaborators Gonorrhea Sexually Transmitted Infections Top Stories

Hygee™ is almost here!

All of us at Earth Science Tech are really excited following the announcement that  Hygee, our first medical device product, is going to have its first commercial production run. We’re only making 5,000 Hygee to start because it’s a full-production test of our manufacturing system, but we’re all pretty confident that things will go fine. We expect to launch Hygee in March, in Vietnam first. It takes a lot of time and paperwork to get a medical device certified in the US and Canada, so our first markets will be in Asia and South America.

What is Hygee?
In case you don’t know, Hygee is a new kind of tool to help women find out if they are infected with Chlamydia, a very serious Sexually Transmitted Infection, or STI, that can have very bad effects on infected women and their babies. The thing is, Chlamydia is easy to cure with antibiotics. What’s hard is getting women tested so they know that they have it. That’s what Hygee does. Hygee makes it very simple for a woman to get tested for Chlamydia (and Gonorrhea soon); quietly, privately, without even the family doctor knowing. If she is infected, she will have to tell a doctor to get treated, but not until then.

Why

Basically, Hygee looks like a very thin menstrual pad, just like the pads that millions of women wear when they have their period; but it’s not a menstrual pad and it can’t be used during menstruation. The kit will be available online or in pharmacies. When a woman wears the Hygee pad for at least four hours (you can wear it all day if you want) the pad collects a cervical cell sample and holds it safely in suspension. Then, she puts the pad in the envelope that comes in the kit, tears the information tab off the envelope, and drops it in the mail. It goes directly to our lab where the actual testing is done. A few days later, all she has to do is either go online or phone the lab. There’s a number on the information tab that she will need to get her results. That’s it. No visit to the doctor, no vaginal swab, no clinic, nobody knows.

Why is all this so important?

It’s important because not only is the disease easily transmitted to sexual partners through unprotected sex, women who are infected and don’t get treatment can have serious heath complications, up to and including sterility! Plus, if a woman is pregnant, Chlamydia is major cause of infants being born blind, or stillborn. We’re not kidding here, this is a serious disease that affects women more than men.

The World Health Organization recommends that all sexually active women aged 15 to 25 years old get tested yearly for Chlamydia. There are more than 130 million new Chlamydia cases yearly, and Hygee is dedicated to helping control the silent Chlamydia epidemic. (We’re going after Gonorrhoea next, but that’s not ready yet.)

So yes, we’re really excited to see the first batch roll off the production line. The whole team believed in the success of Hygee from Day One, and we all feel that we’re not just a business selling a product, we’re doing everything we can to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”

Categories
Feature Story Gonorrhea In the News Latest News Marketing Medical Sexually Transmitted Infections Top Stories

Earth Science Tech LTD (ETST) Promotes Women’s Health with Strategically Branded Self-sampling Kit

DORAL, Florida, Oct. 09, 2018 (GLOBE NEWSWIRE) —

Earth Science Tech LTD (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today details its branding strategy for Hygee™, a medical device designed for the detection of sexually transmitted infections (STIs) in women. With plans to market Hygee™ on five continents, ETST is deploying a striking graphic identity that will speak directly to women.

“From the name of the device to specifics of the logo, our branding strategy reflects the personal yet crucial nature of the Hygee™ self-sampling kit. We wanted to make the brand memorable, yet simple enough to promote its ease-of-use,” states Nickolas S. Tabraue, president, director and chairman of ETST. “Hygee™ is associated with peace of mind, protection, security, health and wellness.”A play on the Greek word for “hygiene,” the name Hygee™ integrates intimacy, confidentiality and discretion. Hygee™ looks like – and is worn like – a standard panty liner. Aptly named, the device allows a woman to discreetly take her own sample for testing to detect STIs, starting with chlamydia.

The positioning of “Personal feminine health test” explains the purpose of the product. Set under the logo, it gives the target market the context needed to better understand the brand.

The tagline, “Accurate, Simple and Discreet,” reflects the personal nature of the product.

ETST CEO and Chief Science Officer Dr. Michel Aubé said, “Hygee™ is designed to preserve women’s health. Our goal is to act upstream to give women the control and the information they need to avoid severe health complications from STI.”

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3330935c-ad09-415b-b662-94d805e17ceb

The Market

While STIs are a serious problem worldwide, the rates of infection across the USA have increased for the third consecutive year, according to the Centers for Disease Control and Prevention. The market for Hygee™ is considerable, as no one uses this technology to perform the 100 million tests for Chlamydia trachomatis done around the world each year. ETST believes Hygee™ will be an ideal tool for high throughput screening of individuals who want to know if they are infected with STIs like chlamydia and gonorrhea. It is accepted that young women are also at higher risk, and this is why ETST will market Hygee™ to target that demographic.

“The best way to fight STIs is prevention, and the only way for women to avoid the dangerous results of untreated STI is early treatment. This means that women need to know if they are infected. We believe that Hygee™ will be the best tool to provide that information. ETST will target specific populations of women globally to better counter the STI epidemic,” said Dr. Aubé.

About Earth Science Tech LTD (ETST)

Earth Science Tech LTD (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market.. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

To learn more, please visit: www.earthsciencetech.com

Categories
Gonorrhea Latest News Marketing Medical Press Releases Sexually Transmitted Infections

ETST:Negotiations underway for MSN-2 and Nanoderm distribution in three countries and plans new clinical study with HIV- seropositive and AIDS patients

Doral, FL, Nov. 30, 2017 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, updated share holders on medical devices  promotion and plans to launch a clinical study with HIV-seropositive and AIDS patients

As previously announced, ETST will initiate the distribution of its medical devices in Djibouti and Morocco (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Announces-New-Agreement-with-Axcelon-Biopolymers-Corp–for-Distribution-of-Nanoderm-trade–Medical-Device–amp–Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y ) while the company waits for regulatory permission to launch in North America.  ETST announces an imminent partnership agreement to develop the Vietnam market for the MSN-2 medical device (branding with original name and graphic environment is coming soon (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Signs-Contract-with-Absolu-to-Advance-Phase-2-Rollout-on-MSN-2-Medical-Device?id=166272&b=y ) and the Nanoderm™ medical device which was developed by a member of the ETST advisory board, Dr. Chandra Panchal (Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of Axcelon Biopolymer: http://axcelonbp.com/companay/board-of-directors/ ). Only some details remain to be discussed and the new Vietnam market partner will be announced in the before year end.

The company is also in discussion to introduce its high-grade CBD hemp oil in the primary launch countries. The first samples of MSN-2 and Nanoderm™ are being sent to those three countries, Djibouti, Morocco and Vietnam, in order to start negotiations with local authorities and partners.

In Vietnam the products will be presented directly to hospital administrators and physicians by ETST’s new American partner who is of Vietnamese origin. This partner, whose name will be announced officially in a few days, has been a distributor of medical devices for many years and saw a huge opportunity working with us.

New clinical study of HIV seropositive and AIDS-infected patients

ETST is planning a clinical study of HIV-seropositive people and AIDS-infected patients in the hope of making as much a difference in the lives of as many people as is possible. The company sees a very good opportunity to help people that are infected with HIV because they suffer from oxidative- related stress and inflammation that are caused by their medical condition. Many HIV patients suffer from chronic pain that requires them to take opioids, or are addicted to opioids. ETST’s CBD rich hemp oil may help them to diminish the quantity of pain relief drugs they need to take and help with the withdrawal from opioids. This project is in line with the clinical study that was just announced this week (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech-Commences-Pre-Launch–Double-Blind-Human-Clinical-Trials-for-New-CBD-Formula-to-Fight-U-S–Opioid-Epidemic?id=176428&b=y ).

In addition, HIV patients are often afflicted by neurological complications that originate from neuro-inflammation. The neuronal protection activity of ETST CBD rich hemp oil has already been proven in vitro by DV Biologics:

http://www.otcmarkets.com/stock/ETST/news/DV-Biologics–a-Leading-Biological-Company–Reports-Earth-Science-Tech–ETST–High-Grade-Hemp-CBD–Cannabidiol–Oil-Reduces-Oxidative-Stress-and-Lipid-Peroxidation-on-Human-Brain-Cells-In-Vitro?id=107954&b=y

The administration of CBD may not only relieve many symptoms resulting from HIV infection and associated medication, but it may also help to retard the development of other HIV-associated diseases. This clinical assay will lay the foundation for the creation of the first CBD rich Hemp Oil product improved with other natural molecules to relieve symptoms and retard diseases in HIV patients.

Further updates concerning the third clinical study and other ETST projects will be issued soon.

 

About Earth Science Tech (ETST)

Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST’s accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

 

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

 

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

 

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it’s unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

 

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

 

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305)-615-2118